Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Adicet Bio Inc (ACET)

Adicet Bio Inc (ACET)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 164,340
  • Shares Outstanding, K 82,170
  • Annual Sales, $ 0 K
  • Annual Income, $ -142,660 K
  • 60-Month Beta 1.88
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.83
Trade ACET with:

Options Overview Details

View History
  • Implied Volatility 131.62% ( -476.80%)
  • Historical Volatility 70.47%
  • IV Percentile 58%
  • IV Rank 14.20%
  • IV High 608.42% on 04/22/24
  • IV Low 52.70% on 05/19/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 17
  • Volume Avg (30-Day) 54
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 1,224
  • Open Int (30-Day) 1,596

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.35
  • Number of Estimates 2
  • High Estimate -0.27
  • Low Estimate -0.43
  • Prior Year -0.72
  • Growth Rate Est. (year over year) +51.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.90 +10.53%
on 04/19/24
2.43 -13.58%
on 04/01/24
-0.09 (-4.11%)
since 03/22/24
3-Month
1.88 +11.70%
on 03/18/24
3.62 -41.99%
on 02/06/24
-0.41 (-16.33%)
since 01/23/24
52-Week
1.10 +90.91%
on 11/29/23
7.50 -72.00%
on 05/10/23
-4.08 (-66.02%)
since 04/21/23

Most Recent Stories

More News
Adicet Bio, Inc. (ACET) Reports Q1 Loss, Misses Revenue Estimates

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 2.70% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ACET : 2.10 (+5.00%)
URGN : 14.15 (-1.53%)
Arcturus Therapeutics (ARCT) Q1 Earnings and Revenues Miss Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -69.86% and 39.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ARCT : 28.46 (+5.17%)
ACET : 2.10 (+5.00%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on April...

ACET : 2.10 (+5.00%)
Legend Biotech Corporation Sponsored ADR (LEGN) Soars 19.6%: Is Further Upside Left in the Stock?

Legend Biotech Corporation Sponsored ADR (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that...

LEGN : 46.45 (-1.30%)
ACET : 2.10 (+5.00%)
Adicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief...

ACET : 2.10 (+5.00%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on March...

ACET : 2.10 (+5.00%)
Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights...

ACET : 2.10 (+5.00%)
Adicet Bio to Participate in 2023 Jefferies Biotech on the Bay Summit

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief...

ACET : 2.10 (+5.00%)
Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates

Akoya (AKYA) delivered earnings and revenue surprises of -21.95% and 1.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AKYA : 3.92 (+0.51%)
ACET : 2.10 (+5.00%)
Myriad Genetics (MYGN) Reports Q4 Loss, Tops Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 25% and 5.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

MYGN : 18.74 (+1.35%)
ACET : 2.10 (+5.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif.

See More

Key Turning Points

3rd Resistance Point 2.13
2nd Resistance Point 2.09
1st Resistance Point 2.05
Last Price 2.10
1st Support Level 1.96
2nd Support Level 1.91
3rd Support Level 1.87

See More

52-Week High 7.50
Fibonacci 61.8% 5.06
Fibonacci 50% 4.30
Fibonacci 38.2% 3.54
Last Price 2.10
52-Week Low 1.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar